4.3 Review

Other iatrogenic immunodeficiency-associated lymphoproliferative disorders in a patient with anti-melanoma differentiation-associated gene 5-positive dermatomyositis: A case report and systematic literature review

Journal

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
Volume 26, Issue 6, Pages 1172-1177

Publisher

WILEY
DOI: 10.1111/1756-185X.14608

Keywords

anti-melanoma differentiation-associated gene 5; dermatomyositis; iatrogenic; lymphoproliferative disorders

Categories

Ask authors/readers for more resources

A 58-year-old man with MDA5-DM developed EBV-associated malignant lymphoma during immunosuppressive therapy. EBV reactivation played a role in the pathogenesis of LPD in this case. Prompt chemotherapy and discontinuation of immunosuppressants resulted in complete remission. This is the first reported case of MDA5-DM complicated with OIIA-LPD. Among 19 similar cases, regression of LPD occurred with withdrawal of immunosuppressants in 7 patients, chemotherapy was required in 9 patients, and 5 patients died.
A 58-year-old man with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5-DM) developed Epstein-Barr virus (EBV)-associated malignant lymphoma as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD) during the combined immunosuppressive therapy of high-dose prednisolone, tacrolimus, and intravenous cyclophosphamide for MDA5-DM. Serum EBV DNA was detected, and EBV-encoded small RNA was positive in the tissue sample of LPD, indicating that EBV reactivation contributed to the pathogenesis of LPD in our case. The patient underwent chemotherapy, including rituximab, promptly after discontinuation of tacrolimus and cyclophosphamide, resulting in complete remission of the malignant lymphoma, and MDA5-DM has not recurred with 3.5 mg/d of prednisolone monotherapy. We reviewed 19 cases of OIIA-LPD in patients with idiopathic inflammatory myopathies and herein report the first case of MDA5-DM complicated with OIIA-LPD. Among the 19 patients, 7 showed regression of LPD only following withdrawal of immunosuppressants, 9 took chemotherapy for LPD, and 5 died. It should be noted that patients with MDA5-DM-associated rapidly progressive interstitial lung disease could develop OIIA-LPD because they receive aggressive immunosuppressive therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available